Edition:
United States

Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.08DKK
18 Aug 2017
Change (% chg)

kr.-0.01 (-0.92%)
Prev Close
kr.1.09
Open
kr.1.09
Day's High
kr.1.09
Day's Low
kr.1.06
Volume
2,355,755
Avg. Vol
1,030,709
52-wk High
kr.1.45
52-wk Low
kr.1.03

VELOX.CO

Chart for VELOX.CO

About

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a Denmark-based commercial-stage specialty pharmaceutical company. The Company operates in the United States (US) through its subsidiary, Veloxis Pharmaceuticals Inc, based in Cary, North Carolina, US. The Company’s products include: Envarsus XR (tacrolimus... (more)

Overall

Beta: 0.05
Market Cap(Mil.): kr.1,840.60
Shares Outstanding(Mil.): 1,709.49
Dividend: --
Yield (%): --

Financials

  VELOX.CO Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -0.03 -- --
ROI: -50.75 2.87 14.88
ROE: -133.42 5.20 16.12

BRIEF-Veloxis Pharmaceuticals H1 revenue $16.17 million

* Veloxis pharmaceuticals a/s says revenue reached $16.17 million in first half of 2017 representing an increase of 394% compared to same period last year

Aug 16 2017

BRIEF-Veloxis Pharmaceuticals A/S, Endo Ventures enter deal to commercialize Envarsus XR in Canada

* Veloxis Pharmaceuticals A/S and Endo Ventures Limited jointly announce agreement for Paladin Labs Inc. To commercialize Envarsus XR® in Canada

Jun 06 2017

BRIEF-Veloxis Pharmaceuticals signs deal with Chiesi Farmaceutici to commercialize Envarsus XR in China

* ANNOUNCES AGREEMENT WITH CHIESI FARMACEUTICI S.P.A. TO COMMERCIALIZE ENVARSUS XR IN CHINA

Jun 06 2017

BRIEF-Veloxis and Endo Ventures announce agreement on commercialization in Canada

* VELOXIS PHARMACEUTICALS A/S AND ENDO VENTURES LIMITED JOINTLY ANNOUNCE AGREEMENT FOR PALADIN LABS INC. TO COMMERCIALIZE ENVARSUS XR® IN CANADA

Jun 05 2017

BRIEF-Veloxis Pharmaceuticals Q1 operating loss narrows to $5.2 mln

* VELOXIS MAINTAINS ITS 2017 OUTLOOK OF OPERATING LOSS BEFORE THE RECOGNITION OF INCOME FROM LICENSE AGREEMENTS AND BEFORE ACCOUNTING FOR STOCK COMPENSATION TO BE IN THE RANGE OF USD 5 – 15 MILLION.

May 17 2017

BRIEF-Veloxis increases share capital in connection with exercise of warrants

* CAPITAL INCREASED BY 1,000,000 NEW SHARES WITH A NOMINAL VALUE OF DKK 0.10 EACH CORRESPONDING TO NOMINALLY DKK 100,000 AS A CONSEQUENCE OF EXERCISE OF WARRANTS

Apr 04 2017

BRIEF-Veloxis Pharmaceuticals announces New Jersey office closure

* US subsidiary, Veloxis Pharmaceuticals Inc., has decided to close its office in Edison, New Jersey effective February 28, 2017

Feb 28 2017

Earnings vs. Estimates